In contrast, IGF-1R/nuclear expression, significantly related to poor survival in patients who did not receive adjuvant chemotherapy, may differentiate a subgroup of SS patients candidate to adjuvant chemotherapy. This evidence concerns the gene IGF1R and synovial sarcoma.